TKNO
Alpha Teknova, Inc.4.6400
+0.0500+1.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
248.38MP/E (TTM)
-Basic EPS (TTM)
-0.33Dividend Yield
0%Recent Filings
8-K
Q3 revenue grows 9%
Alpha Teknova reported third-quarter 2025 revenue of $10.5 million, up 9% from $9.6 million last year, marking five straight quarters of growth amid biotech funding woes. Lab Essentials surged 16% to $8.3 million, offsetting a 13% dip in Clinical Solutions to $1.7 million; gross margin hit 30.7% versus 0.9%, boosted by prior-year inventory charges. Net loss narrowed to $4.3 million from $7.6 million. The company holds $22.1 million in cash and investments against $13.2 million debt. It reaffirms 2025 revenue guidance of $39-42 million. Adjusted EBITDA improved sharply.
10-Q
Q2 FY2025 results
Alpha Teknova posted solid Q2 revenue of $10.3M, up 7.0% y/y from $9.6M, fueled by 31.6% growth in Clinical Solutions while Lab Essentials ticked up 2.0%; gross margin leaped to 38.7% from 29.2% on manufacturing efficiencies. Operating loss narrowed to $3.4M from $5.1M y/y, thanks to 10.1% lower G&A spend, though net loss of $3.6M exceeded operating by $0.2M due to interest expense. YTD revenue climbed 6.2% to $20.1M, with operating loss shrinking 36.2% to $8.4M and diluted EPS improving to -$0.15 from -$0.33 on 53.4M shares. Cash and equivalents stood at $3.3M plus $20.7M in short-term investments, backing $13.0M long-term debt under a March 2025 facility maturing 2030 with $5.0M revolver availability and $39.0M minimum revenue covenant for 2025. Free cash flow not disclosed in the 10-Q. Yet competition from advanced technologies looms large.
8-K
Q2 revenue up 7%, margins improve
Alpha Teknova reported Q2 2025 revenue of $10.3 million, up 7% from $9.6 million in Q2 2024, driven by 32% growth in Clinical Solutions to $2.1 million while Lab Essentials rose 2% to $7.8 million. Gross margin expanded to 38.7% from 29.2%, fueled by manufacturing efficiencies, narrowing net loss to $3.6 million and adjusted EBITDA to negative $0.8 million. Revenue climbed year-over-year for the fourth straight quarter. The company holds $24.0 million in cash and short-term investments against $13.2 million in borrowings, reaffirming 2025 revenue guidance of $39-42 million amid macro uncertainties.
8-K
Annual meeting elects directors
Alpha Teknova's stockholders overwhelmingly elected Martha J. Demski and Alexander Herzick as Class I directors at the June 17, 2025, annual meeting, with 88.62% of shares represented. They also ratified Grant Thornton LLP as auditors for the fiscal year ending December 31, 2025, with near-unanimous support. Directors will serve until 2028. Governance stays steady.
10-Q
Q1 FY2025 results
Alpha Teknova posted Q1 FY2025 revenue of $9.8M, up 5.4% y/y from $9.3M, driven by 11.7% growth in Lab Essentials to $8.1M while Clinical Solutions fell 32.4% to $1.2M; gross profit climbed 36.1% to $3.0M, lifting the margin to 30.7% from 23.8% on lower overhead. Operating loss narrowed to $5.0M from $8.0M, aided by 21.8% cuts in opex, mainly from reduced G&A after last year's workforce reduction and stock repricing. Diluted EPS improved to -$0.09 from -$0.20, matching net loss of $4.6M over 53.4M shares. Cash burn eased to $4.1M from $6.6M, with $3.4M cash and $22.9M short-term investments at quarter-end; free cash flow not disclosed in the 10-Q. In March 2025, the company refinanced its debt into a $28.2M facility maturing 2030, with $13.0M outstanding at Term SOFR +6.45% and $5.0M revolver availability tied to receivables. Yet competition from advanced technologies pressures market share.
IPO
Website
Employees
Sector
Industry
ALKS
Alkermes plc
28.06-0.11
GELS
Gelteq Limited
0.96+0.00
HSTI
High Sierra Technologies Inc.
1.40+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NVO
Novo Nordisk A/S
48.96-1.41
PHBI
Pharmagreen Biotech Inc.
0.00+0.00
SNOA
Sonoma Pharmaceuticals, Inc.
3.38-0.03
TECH
Bio-Techne Corp
57.44-1.25
TEVA
Teva Pharmaceutical Industries
30.10-0.03
ZYBT
Zhengye Biotechnology Holding L
1.86-0.07